MX2021010283A - Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus. - Google Patents
Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.Info
- Publication number
- MX2021010283A MX2021010283A MX2021010283A MX2021010283A MX2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A MX 2021010283 A MX2021010283 A MX 2021010283A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- alcam
- inhibitors
- antibody compositions
- present disclosure
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010025135 lupus erythematosus Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 230000037361 pathway Effects 0.000 abstract 2
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102100024210 CD166 antigen Human genes 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción proporciona métodos para tratar enfermedades inflamatorias o autoinmunes (por ejemplo, nefritis por lupus) usando inhibidores de la vía CD6-ALCAM como por ejemplo EQ001 y con métodos y pruebas de diagnóstico para identificar a sujetos quienes probablemente respondan a estos inhibidores. En particular, la presente descripción proporciona usos de diagnóstico y terapéuticos relacionados con niveles elevados de ALCAM soluble y/o proteína CD6 y fragmentos de proteína en orina y otras muestras biológicas que son indicativos de sensibilidad a inhibidores de la vía CD6-ALCAM (por ejemplo, EQ001).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810628P | 2019-02-26 | 2019-02-26 | |
| US201962933294P | 2019-11-08 | 2019-11-08 | |
| PCT/US2020/019990 WO2020176682A1 (en) | 2019-02-26 | 2020-02-26 | Anti-cd6 antibody compositions and methods for treating lupus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010283A true MX2021010283A (es) | 2021-09-30 |
Family
ID=70009403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010283A MX2021010283A (es) | 2019-02-26 | 2020-02-26 | Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220143140A1 (es) |
| EP (1) | EP3930751A1 (es) |
| JP (1) | JP2022521973A (es) |
| CN (1) | CN113490511B (es) |
| AU (1) | AU2020229830A1 (es) |
| BR (1) | BR112021016967A2 (es) |
| CA (1) | CA3131299A1 (es) |
| MX (1) | MX2021010283A (es) |
| PH (1) | PH12021551994A1 (es) |
| SG (1) | SG11202109118XA (es) |
| WO (1) | WO2020176682A1 (es) |
| ZA (1) | ZA202107077B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ587632A (en) | 2008-03-14 | 2012-06-29 | Biocon Ltd | An anti-cd6 monoclonal antibody and a method thereof |
| CN119630966A (zh) * | 2022-05-25 | 2025-03-14 | 休斯敦系统大学 | 用于对膀胱癌进行风险分层和管理的方法和系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998172A (en) * | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CU22584A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| IL130864A0 (en) * | 1997-03-03 | 2001-01-28 | Bristol Myers Squibb Co | Monoclonal antibodies to human cd6 |
| AU2007336564B2 (en) * | 2006-12-26 | 2012-11-01 | Centro De Inmunologia Molecular | Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-Chronic Lymphocytic Leukaemia |
| NZ587632A (en) * | 2008-03-14 | 2012-06-29 | Biocon Ltd | An anti-cd6 monoclonal antibody and a method thereof |
| AU2012279225A1 (en) * | 2011-07-01 | 2014-01-16 | Beckman Coulter, Inc. | Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders |
| EP2822970A1 (en) * | 2012-03-08 | 2015-01-14 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| EP3097419B1 (en) * | 2014-01-20 | 2018-03-14 | Pad 4 Di Emanuele Ghiggeri S.A.S. | In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis |
| KR102395093B1 (ko) * | 2016-04-04 | 2022-05-04 | 케모센트릭스, 인크. | 가용성 C5aR 길항제 |
| PT3468997T (pt) * | 2016-06-08 | 2023-12-07 | Debra Zack | Tratamento de doenças relacionadas com igg4 com anticorpos anti-cd19 com ligação cruzada a cd32b |
| US11242401B2 (en) * | 2016-10-21 | 2022-02-08 | Biocon Limited | Monoclonal antibody and a method of use for the treatment of lupus |
-
2020
- 2020-02-26 US US17/434,247 patent/US20220143140A1/en active Pending
- 2020-02-26 WO PCT/US2020/019990 patent/WO2020176682A1/en active Application Filing
- 2020-02-26 SG SG11202109118XA patent/SG11202109118XA/en unknown
- 2020-02-26 MX MX2021010283A patent/MX2021010283A/es unknown
- 2020-02-26 CN CN202080016831.1A patent/CN113490511B/zh active Active
- 2020-02-26 JP JP2021549772A patent/JP2022521973A/ja active Pending
- 2020-02-26 BR BR112021016967A patent/BR112021016967A2/pt unknown
- 2020-02-26 PH PH1/2021/551994A patent/PH12021551994A1/en unknown
- 2020-02-26 EP EP20714769.5A patent/EP3930751A1/en active Pending
- 2020-02-26 CA CA3131299A patent/CA3131299A1/en active Pending
- 2020-02-26 AU AU2020229830A patent/AU2020229830A1/en active Pending
-
2021
- 2021-09-22 ZA ZA2021/07077A patent/ZA202107077B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020229830A1 (en) | 2021-09-16 |
| CN113490511A (zh) | 2021-10-08 |
| EP3930751A1 (en) | 2022-01-05 |
| US20220143140A1 (en) | 2022-05-12 |
| CN113490511B (zh) | 2024-07-09 |
| CA3131299A1 (en) | 2020-09-03 |
| PH12021551994A1 (en) | 2022-08-15 |
| ZA202107077B (en) | 2023-07-26 |
| WO2020176682A1 (en) | 2020-09-03 |
| JP2022521973A (ja) | 2022-04-13 |
| BR112021016967A2 (pt) | 2021-11-23 |
| SG11202109118XA (en) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spengler et al. | Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid | |
| Gao et al. | VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer | |
| Ayllon et al. | Systems biology of tissue-specific response to Anaplasma phagocytophilum reveals differentiated apoptosis in the tick vector Ixodes scapularis | |
| Salpeter et al. | A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression | |
| Badot et al. | Serum soluble interleukin 7 receptor is strongly associated with lupus nephritis in patients with systemic lupus erythematosus | |
| BRPI0708101B1 (pt) | anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico | |
| EA201790087A1 (ru) | Ковалентно связанные диатела, обладающие иммунореактивностью с pd-1 и lag-3, и способы их применения | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| EP3750916A3 (en) | Anti-dengue virus ns1 protein monoclonal antibodies | |
| EA201891178A1 (ru) | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения | |
| EA201590630A1 (ru) | Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2) | |
| EA200971131A1 (ru) | Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам | |
| EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| Zeitvogel et al. | GATA3 regulates FLG and FLG2 expression in human primary keratinocytes | |
| BR112017017076A2 (pt) | inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre. | |
| BR112013028779B8 (pt) | proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição | |
| EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
| ECSP11011297A (es) | Proteinas ligadoras il-17 | |
| EA200801679A1 (ru) | Композиции и способы применения антител к dickkopf-1 и/или -4 | |
| MX2024005669A (es) | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano. | |
| ES2657414T3 (es) | Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer | |
| BR112022003335A2 (pt) | Conjugados de il-2 e métodos de uso para tratar doenças autoimunes | |
| MX2021010283A (es) | Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus. | |
| EA202092088A1 (ru) | Антитела анти-phf-тау и их применение |